News Release

For Immediate Release – April 11, 2024

APPRAISE-HRI, an artificial intelligence enabled decision-support application for military health care providers to stratify hemorrhage risk of US Service Members after a traumatic event, cleared by the U.S. FDA

FORT DETRICK, Md. – The U.S. Army Medical Research and Development Command's Biotechnology High Performance Computing Software Applications Institute recently obtained FDA clearance of the Automated Processing of the Physiological Registry for Assessment of Injury Severity-Hemorrhage Risk Index software as a medical device.

APPRAISE-HRI is a mobile health application intended to help military health care providers screen U.S. Service Members for hemorrhage risk after a physically traumatic event and stratify casualties who need immediate attention and emergency evacuation from those who are injured but may not be at risk for hemorrhage.

APPRAISE-HRI is not intended to diagnose or direct treatment. Rather, it is intended to serve as a risk assessment tool and to provide situational awareness and inform clinical management of potentially hemorrhagic casualties by identifying those at the greatest risk of hemorrhage.

This research effort was sponsored by the U.S. Army Combat Casualty Care Research Program, which funded the research, and the U.S. Army Medical Materiel Development Activity, which provided funding for the regulatory activities with the FDA, with support from the Defense Health Program. This important milestone is the result of an interagency agreement sponsored by the Warfighter Expeditionary Medicine and Treatment Project Management Office, part of USAMMDA. The agreement was established in support of the Defense Health Agency's Advanced Medical Monitor Family of Systems program, which aims to provide far-forward medical monitoring capability to the joint services.

The MRDC Office of Regulated Activities provided support with the interactions between the FDA and the BHSAI. The Medical Technology Transfer Office is seeking to license this technology, for which the U.S. Army holds three U.S. patents, with interested commercial partners.

-END-

About BHSAI:
The Biotechnology High Performance Computing Software Applications Institute develops computational solutions to accelerate research in the broader Department of Defense biotechnology and medical community. The Institute has a multidisciplinary staff with previous working experience in industry, government, and academia and expertise in artificial intelligence, bioinformatics, computer science, modeling and control, physical chemistry, physics, mathematics, biophysics, biomedical engineering, biochemistry, systems biology, cellular biology, physiology, and medicine. Our broad scientific expertise and biological problem-solving skills, coupled with the computational power of the DOD supercomputing assets, provide a unique environment for cutting-edge, computational-experimental interdisciplinary research. For more information on BHSAI, please visit: bhsai.org.

About USAMRDC:
USAMRDC is the Army's medical materiel developer, with responsibility for medical research, development and acquisition in a variety of areas integral to Soldier health and resiliency. For more information, visit: mrdc.health.mil.